Incretins: all 1,182 studies that test it

Page 11 of 12. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• Effect of Liraglutide on Heart Frequency in Healthy VolunteersCompletedNCT01516255Phase 1
• Safety and Tolerability of Liraglutide in Healthy Japanese Male VolunteersCompletedNCT01515592Phase 1
• Comparison of Two Liraglutide Formulations in Healthy SubjectsCompletedNCT01515579Phase 1
• Bioequivalence of Two Liraglutide Formulations in Healthy VolunteersCompletedNCT01515553Phase 1
• Comparison of Three Liraglutide Formulations in Healthy VolunteersCompletedNCT01514487Phase 1
• Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy VolunteersCompletedNCT01513525Phase 1
• Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 DiabetesCompletedNCT01511692Phase 1
• Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic AgentCompletedNCT01511198Phase 2
• Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control GroupCompletedNCT01511185Phase 1
• Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 DiabetesCompletedNCT01511172Phase 2
• Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male VolunteersCompletedNCT01511159Phase 1
• Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 DiabetesCompletedNCT01509755Phase 2
• Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 DiabetesCompletedNCT01509742Phase 1
• Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 DiabetesCompletedNCT01508949Phase 2
• Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT01508923Phase 2
• Comparison of Two Liraglutide Formulations in Healthy VolunteersCompletedNCT01508897Phase 1
• Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal WomenCompletedNCT01508858Phase 1
• Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney FunctionCompletedNCT01508806Phase 1
• Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver FunctionCompletedNCT01507389Phase 1
• Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy VolunteersCompletedNCT01507337Phase 1
• Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 DiabetesCompletedNCT01507311Phase 1
• Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 DiabetesCompletedNCT01507285Phase 1
• Safety and Tolerability of Liraglutide in Healthy Male VolunteersCompletedNCT01507272Phase 1
• Effects of the GLP-1 Exenatide on Satiety in Lean and Obese WomenCompletedNCT01501084Phase 1
• Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 DiabetesCompletedNCT01499108Phase 4
• Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic PatientsCompletedNCT01473147Not applicable
• The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes MellitusCompletedNCT01472640Not applicable
• Identifying Potential Effects of Liraglutide on Degenerative ChangesCompletedNCT01469351Not applicable
• The Effect of Glucagon Like Peptide (GLP)-1 in PsoriasisCompletedNCT01460069Not applicable
• A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesWithdrawnNCT01455922Phase 3
• A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesWithdrawnNCT01455909Phase 3
• A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650CompletedNCT01455896Phase 3
• A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesWithdrawnNCT01455883Phase 3
• A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesCompletedNCT01455870Phase 3
• A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesCompletedNCT01455857Phase 3
• GLP-1 Receptors in Normal Skin and Skin From Patients With PsoriasisStatus unknownNCT01451905Not applicable
• Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin ProducCompletedNCT01441869Phase 1
• A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsCompletedNCT01441232Phase 1
• Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 DiabetesStatus unknownNCT01435980Phase 4
• Liraglutide and Heart Failure in Type 2 DiabetesCompletedNCT01425580Phase 2
• Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and SitagliptinCompletedNCT01422590Phase 1
• Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes MellitusCompletedNCT01414920Phase 2
• Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 DiabetesCompletedNCT01399645Phase 2
• Liraglutide Treatment to Patients With Severe Renal InsufficiencyCompletedNCT01394341Phase 4
• Liraglutide and Insulin Therapy in Patients With Type 2 DiabetesStatus unknownNCT01392898Not applicable
• Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary BypassCompletedNCT01373216Phase 3
• Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and InsulinCompletedNCT01341717Phase 4
• Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver DiseasesStatus unknownNCT01337440Phase 4
• Metformin and Sitagliptin in Women With Previous Gestational DiabetesCompletedNCT01336322Phase 2
• Effects of Saxagliptin on Endothelial FunctionCompletedNCT01319357Phase 3
• Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy SubjectsCompletedNCT01319240Phase 1
• BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed StatesWithdrawnNCT01305551Phase 1
• Effects of Alogliptin on Pancreatic Beta Cell FunctionStatus unknownNCT01303055Not applicable
• GLP Analogs for Diabetes in Wolfram Syndrome PatientsWithdrawnNCT01302327Not applicable
• The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and DiabetesCompletedNCT01281228Not applicable
• LIraglutide and Beta-cell RepAir (LIBRA) StudyCompletedNCT01270789Phase 3
• The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsStatus unknownNCT01270191Phase 4
• Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe HyperglycemiaCompletedNCT01267448Phase 4
• Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 DiabetesTerminatedNCT01260246Not applicable
• Sitagliptin in Cystic Fibrosis-Related DiabetesTerminatedNCT01257464Phase 2
• Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)Status unknownNCT01254123Phase 3
• Liraglutide Efficacy and Action in Non-Alcoholic SteatohepatitisCompletedNCT01237119Phase 2
• Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes MellitusCompletedNCT01235819Phase 4
• Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT01208649Phase 4
• Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes MellitusCompletedNCT01208012Phase 4
• Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes MellitusStatus unknownNCT01206647Phase 4
• Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) EffectsStatus unknownNCT01176890Not applicable
• Exendin-4 as a Treatment for Parkinson's Disease - Pilot StudyStatus unknownNCT01174810Phase 2
• Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)CompletedNCT01159847Phase 1/2
• Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 DiabetesStatus unknownNCT01140893Phase 2/3
• Treatment of Latent Autoimmune Diabetes of the AdultCompletedNCT01140438Not applicable
• A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy SubjectsCompletedNCT01104532Phase 1
• Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin TreatmentCompletedNCT01100125Phase 4
• Vascular Effects of Sitagliptin in Diabetes MellitusStatus unknownNCT01096277Phase 4
• Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes MellitusCompletedNCT01095991Phase 1
• Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentCompletedNCT01076842Phase 4
• Role of Interleukin-6 in ExerciseCompletedNCT01073826Not applicable
• Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in HumansCompletedNCT01056549Not applicable
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and SitagliptinCompletedNCT01054118Phase 1
• Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?CompletedNCT01048268Phase 1/2
• Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its MechanismsCompletedNCT01046721Not applicable
• Sitagliptin in Prevention of Type 2 Diabetes MellitusWithdrawnNCT01038648Phase 3
• A Two Part Trial Investigating the Safety of NN9924 in Healthy Male SubjectsCompletedNCT01037582Phase 1
• Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 DiabetesCompletedNCT00993720Phase 2/3
• A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 DiabeticsCompletedNCT00993304Phase 1
• Safety and Tolerability of NN9068 in Healthy Male VolunteersCompletedNCT00983021Phase 1
• Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 DiabetesCompletedNCT00978796Phase 4
• A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersCompletedNCT00978393Phase 1
• A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)CompletedNCT00975052Phase 1
• Effects of Exenatide on Postprandial Hyperlipidemia and InflammationCompletedNCT00974272Phase 4
• Predictive Parameters for Efficacy of Sitagliptin and Metformin CombinationCompletedNCT00969566Phase 4
• Effect of Sitagliptin on Endothelial Progenitor CellsCompletedNCT00968006Phase 4
• A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) ExenatideCompletedNCT00964262Phase 1
• Effect of Sitagliptin in Impaired Glucose ToleranceStatus unknownNCT00961363Phase 2
• Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of SitagliptinCompletedNCT00960453Phase 1
• The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 DiabetesCompletedNCT00950677Phase 4
• Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell FunctionCompletedNCT00949663Phase 1
• Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 DiabetesCompletedNCT00948168Phase 4
• Safety of Liraglutide in Pediatric Patients With Type 2 DiabetesCompletedNCT00943501Phase 1
• Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.CompletedNCT00940134Not applicable

← Incretins overview